BPC-157 arginate vs acetate: what the salt form changes

Published 4 November 2026

BPC-157 is sold in two main forms: BPC-157 acetate, the usual form in research vials, and BPC-157 arginate, used mostly in capsules. Both contain the same 15-amino-acid peptide. What differs is the small molecule paired with it to form a salt. This guide explains what that changes, what the published data actually show, and where the evidence stops.

At a glance

What a "salt form" is

Peptides carry electric charges on some of their amino acids, so after synthesis they are isolated as salts: the peptide plus an oppositely charged partner, called the counter-ion. Synthetic peptides usually come off the purification column as trifluoroacetate salts and are then exchanged to acetate, which is the standard form for research and many approved peptide drugs.

BPC-157 has more acidic groups (one glutamate and two aspartates) than basic ones (a single lysine), so it can also pair with basic partners. That is what both BPC-157 salt patents do: the 1997 patent from the Zagreb group that first studied the peptide used sodium and organic amines, and a 2013 patent from the Slovenian company Diagen used basic amino acids, preferably L-arginine. The arginate sold for research corresponds to the di-L-arginine salt described there, abbreviated Arg-BPC.

What the stability data show

The only published head-to-head comparison is in the arginate patent itself. It compared the acetate, the sodium salt and Arg-BPC under the same conditions:

• In water at 50 °C: after 388 hours, 21% of the acetate was left intact, against 97% of the sodium salt and 99% of Arg-BPC.
• In water at 100 °C for one hour: 57% of the acetate remained, against 99% for both the sodium salt and Arg-BPC.
• As a solid at 50 °C and 65% humidity for 90 days: the acetate fell to about 86%, the sodium salt to 97%, Arg-BPC stayed at 99%.
• In artificial gastric juice with pepsin at 37 °C: at pH 3, about 85% of Arg-BPC was intact after 5 hours, compared with 10% of the sodium salt and almost none of the acetate. At pH 4 the gap was smaller (67% against 38% for the acetate after 8 hours). At pH 2, the most acidic test, all three forms were almost completely degraded within 2.5 hours.

Two things explain most of this. The acetate dissolves to an acidic solution, and the patent reports BPC-157 is most stable between pH 6.5 and 8.5, which is where the arginate and sodium salts sit. The arginate adds a further advantage over the sodium salt in mildly acidic gastric conditions.

Keep in mind that these are the applicant's own tests, published in a patent rather than a peer-reviewed journal, and they have not been independently repeated.

Why arginate is used for oral research

BPC-157 is unusual among peptides because it is active in animal studies when given by mouth. The Zagreb group has reported effects in rats with the peptide given in drinking water or directly into the stomach, in models of stomach, intestinal and oesophageal damage among others. Part of the interest in more stable salts comes from this: a form that survives longer in the stomach should, in principle, leave more intact peptide to act in the gut or be absorbed.

That is why capsule products use the arginate. Mixed with fillers and kept dry, it also holds up far better on the shelf than an acetate would.

What is not proven

• Oral bioavailability: no published study has measured how much BPC-157, in any salt form, reaches the bloodstream after oral dosing. Figures quoted online, such as "seven times more bioavailable" or "over 90%", have no primary source we could find. The arginate patent argues for better absorption but contains no blood-level data.
• Better effects: no study has compared the arginate and the acetate head to head for any biological outcome. The animal experiments in the arginate patent used only Arg-BPC.
• Pharmacokinetics in general: the only full study, in rats and dogs, used injections. It found an elimination half-life under 30 minutes and intramuscular bioavailability of about 14–19% in rats and 45–51% in dogs.
• Human data: BPC-157 has no completed controlled human trials in any form, and it is not approved as a medicine anywhere.

Weighing and labelling

Because two arginine molecules add weight, about 80% of a given mass of Arg-BPC is the peptide itself, against about 96% for a monoacetate. When comparing products or planning an experiment, check whether the stated amount refers to the peptide or to the whole salt; the certificate of analysis should make this clear. Our guide to reading a certificate of analysis explains what to look for.

Which form for which research

• Acetate in vials is supplied as lyophilised powder for reconstitution, the format used for injection research. Because it is least stable in solution, keep reconstituted vials cold and use them within the usual window; see our storage guide.
• Arginate in capsules suits oral and gut-focused research, where stability in acid and on the shelf matters most.

For how BPC-157 itself works and how it compares with TB-500, see BPC-157 vs TB-500.

Regulatory status

BPC-157 in any salt form is not approved as a medicine in the EU, the UK or the US. It is sold for laboratory research only.

References

1. Rucman R (Diagen d.o.o.). Stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy. WO 2014/142764 (2014); US Patent 9,850,282 B2 (2017).
2. Sikiric P et al. BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy. US Patent 6,288,028 (2001); WO 1998/052973.
3. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022;13:1026182.
4. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals 2025;18(2):185.
5. Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011;17(16):1612–1632.
6. Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025.

For laboratory research use only. This guide summarises published research and is not medical advice. Our products are not for human consumption.